Drug Profile
Dendritic cell vaccine - Argos Therapeutics/Pharmstandard
Alternative Names: AGS003-like therapyLatest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator Argos Therapeutics Inc
- Class Cancer vaccines; Dendritic cell vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Renal cell carcinoma
Most Recent Events
- 26 Sep 2023 Discontinued - Preclinical for Renal cell carcinoma in Russia (unspecified route)
- 26 Sep 2023 Discontinued - Preclinical for Renal cell carcinoma in USA (unspecified route)
- 28 Dec 2020 No recent reports of development identified for preclinical development in Renal-cell-carcinoma in Russia